Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial

无容量 医学 易普利姆玛 内科学 肿瘤科 随机对照试验 临床研究阶段 神经内分泌肿瘤 临床试验 免疫疗法 化疗 转移性黑色素瘤 总体生存率 单克隆抗体 抗体 护理标准
作者
Thomas Walter,Julien Mazieres,Josiane Otto,H. Léna,Côme Lepage,D. Smith,J. Madelaine,L. Gérinière,Thomas Egenod,Farid El Hajbi,Aurélie Ferru,Christelle Clément-Duchene,A. Madroszyk,Thibault Brotelle,Karine Bouhier-Leporrier,Jérôme Desrame,François Ghiringhelli,N. Paleiron,Antoine Khalil,Laurent Milot
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (12): 1120-1129
标识
DOI:10.1200/jco-25-01657
摘要

PURPOSE: There is no standard second-line therapy for gastroenteropancreatic (GEP) and lung large-cell neuroendocrine carcinoma (NEC) after the failure of platinum-based chemotherapy. This study aimed to investigate the efficacy of nivolumab ± ipilimumab. METHODS: The GCO-001-NIPINEC (ClinicalTrials.gov identifier: NCT03591731) trial was a noncomparative, open-label, phase II trial. The main inclusion criteria were age ≥18 years, performance status (PS) ≤2, advanced large- and small-cell GEP-NEC and large-cell lung NEC, and second- or third-line treatment for NECs refractory to platinum-based chemotherapy. Patients were randomly assigned (1:1) and stratified by age and PS to receive nivolumab (3 mg/kg/once every 2 weeks) ± ipilimumab (1 mg/kg/once every 6 weeks) for 2 years or until progression or unacceptable toxicity. The primary end point was objective response rate (ORR) at 8 weeks, assessed by investigators. RESULTS: A total of 185 patients (91 in the nivolumab arm and 94 in the nivolumab-ipilimumab arm) were enrolled between December 2018 and March 2021; 169 were analyzed (median age of 64.5 years, 71% male, 91% PS 0-1). The main primary tumor locations were lungs (50%), colorectal (15%), gastroesophageal (14%), and pancreatic (13%) regions. The ORR at 8 weeks was 7.2% (95% CI, 2.7 to 15.1]) in the nivolumab arm and 14.0% (95% CI, 7.4 to 23.1) in the nivolumab-ipilimumab arm. The best ORR was 9.6% and 20.9%, respectively, whereas the median progression-free and overall survival were approximately 2 months and 6 months in both arms. One treatment-related death occurred, in the nivolumab arm. The grade 3-4 adverse events (≥5%) were asthenia (13%), gamma-glutamyl transferase increase (10%), alkaline phosphatase increase (9%), dyspnea (7%), and anemia (6%) in the nivolumab-ipilimumab arm. CONCLUSION: Nivolumab-ipilimumab could be a second-/third-line treatment option for patients with NECs. However, given the limited magnitude of benefit, studies are warranted to evaluate its use earlier and/or associated with chemotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
自由的冰夏完成签到 ,获得积分10
1秒前
星星完成签到,获得积分10
1秒前
余香的应助被笃行致远采纳,获得10
1秒前
2秒前
3秒前
哈哈哈哈哈完成签到 ,获得积分10
3秒前
耶耶耶发布了新的文献求助10
3秒前
机灵的成协完成签到,获得积分10
3秒前
4秒前
1234发布了新的文献求助10
4秒前
6秒前
tan完成签到,获得积分10
8秒前
kjh发布了新的文献求助10
8秒前
8秒前
8秒前
8秒前
千里洛发布了新的文献求助10
9秒前
FUTURE发布了新的文献求助10
10秒前
10秒前
Lucas发布了新的文献求助30
11秒前
11秒前
Qwww关注了科研通微信公众号
12秒前
12秒前
12秒前
13秒前
Orange的应助被健康的可仁采纳,获得10
14秒前
14秒前
烟花的应助被迷路达采纳,获得10
15秒前
多少发布了新的文献求助10
16秒前
Lina发布了新的文献求助10
16秒前
17秒前
FFF完成签到,获得积分10
17秒前
18秒前
欢喜代桃发布了新的文献求助10
19秒前
小蜜蜂完成签到 ,获得积分10
20秒前
20秒前
秀丽白玉发布了新的文献求助10
21秒前
yuyu完成签到 ,获得积分10
22秒前
22秒前
所所的应助被奋斗断秋采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189615
求助须知:如何正确求助?哪些是违规求助? 9576892
关于积分的说明 21850083
捐赠科研通 7787512
什么是DOI,文献DOI怎么找? 3435723
关于科研通互助平台的介绍 2559813
邀请新用户注册赠送积分活动 2482616